Topic: Calibr-Skaggs
-
Calibr advances multiple clinical programs while securing significant funding for global health and other disease initiatives
2022 year-end roundup: Clinical success and consistent funding validate Calibr’s pioneering approach to drug discovery.
-
Drug discovery method identifies naturally occurring metabolite that converts ‘bad’ fat to ‘good’ fat
Scripps Research and Calibr scientists collaborate to uncover potential therapeutic avenues for metabolic diseases.
-
‘Scavenger’ cells in the nervous system linked to rare genetic disease
Calibr, the drug development arm of Scripps Research, and other collaborators find microglia play a critical role in SMA disease progression.
-
Calibr reports promising results from first-in-human clinical trial of switchable CAR-T (CLBR001 + SWI019), a next-generation universal CAR-T platform designed to enhance the versatility and safety of cell therapies
Calibr has announced encouraging preliminary data from the first nine subjects in a first-in-human Phase 1 clinical trial studying the first switchable CAR-T cell product (CLBR001 + SWI019) for patients with B cell malignancies.
-
Travis Young: Finding a cure for cancer with novel immunotherapies
Dr. Travis Young is the Vice President of Biologics at Calibr, the drug discovery and development division of Scripps Research. Travis and the team have created a new type of immunotherapy called "switchable" chimeric antigen receptor (CAR) T-cell therapy, which is already delivering precise and powerful therapies to patients with the most difficult to treat cancers. Listen as we talk about reengineering an individual’s immune T cells, promising clinical trials in leukemia and lymphoma patients, and using similar approaches to treat autoimmune diseases.
-
Scripps Research awarded $67 million by NIH to lead new pandemic preparedness center
The multidisciplinary center will focus on development of antiviral drugs to combat coronaviruses and other viruses with pandemic potential.
-
AbbVie and Scripps Research announce collaboration to develop antiviral treatments for COVID-19
Global collaboration seeks to develop potential novel, direct-acting antiviral treatments for COVID-19.
-
Calibr Announces Preliminary Clinical Data from First-in-Human Clinical Trial of Switchable CAR-T Cells
Two of the first three patients in the lowest dose cohort experienced a complete response to therapy.
-
Calibr partners with Wellcome Trust to create consortium for neglected tropical diseases
Collaboration aims to generate new drug candidates for neglected tropical diseases across the globe.
-
Extensive study identifies over a dozen existing drugs as potential COVID-19 therapies
FDA-approved drugs or experimental drugs with ample health data could be rapidly tested in humans for treatment of COVID-19.